Literature DB >> 14741292

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides.

Laval Chan1, Oswy Pereira, T Jagadeeswar Reddy, Sanjoy K Das, Carl Poisson, Marc Courchesne, Mélanie Proulx, Arshad Siddiqui, Constantin G Yannopoulos, Nghe Nguyen-Ba, Caroline Roy, Daniel Nasturica, Christophe Moinet, Richard Bethell, Martine Hamel, Lucille L'Heureux, Maud David, Olivier Nicolas, Philippe Courtemanche-Asselin, Stéphanie Brunette, Darius Bilimoria, Jean Bédard.   

Abstract

Further SAR studies on the thiophene-2-carboxylic acids are reported. These studies led to the identification of a series of tertiary amides that show inhibition of both HCV NS5B polymerase in vitro and HCV subgenomic RNA replication in Huh-7 cells. Structural insights about the bioactive conformation of this class of molecules were deduced from a combination of modeling and transferred NOE (trNOE) studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741292     DOI: 10.1016/j.bmcl.2003.10.068

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

1.  In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Authors:  Oliver Lenz; Thierry Verbinnen; Tse-I Lin; Leen Vijgen; Maxwell D Cummings; Jimmy Lindberg; Jan Martin Berke; Pascale Dehertogh; Els Fransen; Annick Scholliers; Katrien Vermeiren; Tania Ivens; Pierre Raboisson; Michael Edlund; Susan Storm; Lotta Vrang; Herman de Kock; Gregory C Fanning; Kenneth A Simmen
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Authors:  Hongmei Mo; Liangjun Lu; Tami Pilot-Matias; Ron Pithawalla; Rubina Mondal; Sherie Masse; Tatyana Dekhtyar; Teresa Ng; Gennadiy Koev; Vincent Stoll; Kent D Stewart; John Pratt; Pam Donner; Todd Rockway; Clarence Maring; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees.

Authors:  Steven S Carroll; Steven Ludmerer; Larry Handt; Kenneth Koeplinger; Nanyan Rena Zhang; Donald Graham; Mary-Ellen Davies; Malcolm MacCoss; Daria Hazuda; David B Olsen
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

4.  Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.

Authors:  Frederik Pauwels; Wendy Mostmans; Ludo M M Quirynen; Liesbet van der Helm; Carlo W Boutton; Anne-Stéphanie Rueff; Erna Cleiren; Pierre Raboisson; Dominique Surleraux; Origène Nyanguile; Kenneth A Simmen
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

Review 5.  Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.

Authors:  H Le Guillou-Guillemette; S Vallet; C Gaudy-Graffin; C Payan; A Pivert; A Goudeau; F Lunel-Fabiani
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

6.  Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.

Authors:  Julie Qi Hang; Yanli Yang; Seth F Harris; Vincent Leveque; Hannah J Whittington; Sonal Rajyaguru; Gloria Ao-Ieong; Matthew F McCown; April Wong; Anthony M Giannetti; Sophie Le Pogam; Francisco Talamás; Nick Cammack; Isabel Nájera; Klaus Klumpp
Journal:  J Biol Chem       Date:  2009-02-26       Impact factor: 5.157

7.  Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.

Authors:  Tanaji T Talele; Payal Arora; Shridhar S Kulkarni; Maulik R Patel; Satyakam Singh; Maksim Chudayeu; Neerja Kaushik-Basu
Journal:  Bioorg Med Chem       Date:  2010-05-15       Impact factor: 3.641

8.  Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase.

Authors:  Amaravadhi Harikishore; Enlin Li; Jia Jun Lee; Nam-Joon Cho; Ho Sup Yoon
Journal:  Mol Divers       Date:  2015-04-11       Impact factor: 2.943

9.  Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.

Authors:  Sophie Le Pogam; Hyunsoon Kang; Seth F Harris; Vincent Leveque; Anthony M Giannetti; Samir Ali; Wen-Rong Jiang; Sonal Rajyaguru; Gisele Tavares; Connie Oshiro; Than Hendricks; Klaus Klumpp; Julian Symons; Michelle F Browner; Nick Cammack; Isabel Nájera
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

10.  Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.

Authors:  Steven W Ludmerer; Donald J Graham; Evelyn Boots; Edward M Murray; Amy Simcoe; Eric J Markel; Jay A Grobler; Osvaldo A Flores; David B Olsen; Daria J Hazuda; Robert L LaFemina
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.